Unlike biologic vaccines, Inovio's vaccines are comprised of computer-generated strands of synthetic DNA mixed with water. This works to give Inovio's product candidates a huge edge, as these synthetic therapies don't run the risk of producing the viruses which they aim to treat and can also be easily manufactured and stored at room temperature. Likewise, being that these vaccines are synthetic and not biologic has enabled Inovio to build a large IP and patent portfolio for its products. Currently the company's pipeline hosts over 400 patents and shows no sign of slowing its IP expansion. Specifically what Inovio has been patenting so aggressively thus far are its coded DNA sequences which are the foundational mechanism of action for its vaccines and therapies. Through these synthesized DNA transcription codes, Inovio's vaccines work to activate targeted immunological responses triggering the patient's own body to fight their disease more effectively. Along with the numerous published studies demonstrating the efficacy of the company's technology, recent pre-clinical data revealed that the company's hTERT DNA cancer vaccine generated a T-Cell immune system response 18-fold higher than the next best peer technology found in Merck's (MRK) DNA Plus Adenovirus Vector.
I think the part most people over look is a computer designs the vaccine and my bet is if one vaccine goes to market I think all of them will with the exception of AIDS. Only because from what I've read is that even in a body where it has a immune response it only last for a time and then the virus changes and wins. But I do believe that this is the beginning of a cure. With that said I believe that with the computer program they have they are years ahead of the big company's and will continue to dominate with new patens, until we see a big buyout maybe as early as 6 month. But no later that the first vaccine going to market. In two years the expect the vaccine market to double and by 2022 they expect it to quadruple. I feel there are a lot of cash fat companies that need the patens that this company holds. The big one being the computer program.
A combo of a CXCR4/CCL5 inhibitor (what the virus uses to attach to target cells) and an HIV vaccine to attack the virally infected cells may be the best bet to get rid of infected cells while preventing newly made cells from the bone marrow from being infected. AMD3100 is a CXCR4 inhibitor used for bone marrow transplant donors to mobilize stem cells to give to people receiving the bone marrow transplant. Another option is an integrase inhibitor (prevents virus from integrating their genome into the cells genome) in combo with a vaccine. The key is to get rid of the reservoir of infected cells which includes hematopoietic stem cells, dendritic cells, and astrocytes/microglia in the CNS. Just a couple of out there thoughts.
Great post Gary. I have read this before and one of the things that really stands out is "can also be easily manufactured and stored at room temperature. " This is a huge deal for the 3rd world and remote areas. Refrigeration is a big problem for current vaccine tech. in these areas. The Gate foundation partnered with a company that developed a cooler packed with ice that could last 35 days just for this reason.